[IL-2 gene and cisplatin combined therapy for head and neck squamous cell carcinoma].
The objective of this study is to assess the efficacy of IL-2 gene and cisplatin combined therapy on murine HNSCC models. HNSCC tumors were established in murine models. The sizes of tumors were measured before and after combined IL-2 and cisplatin treatment, and the results were evaluated by comparing different single treatment groups and the control IL-2 expression was measured after IL-2 gene transfer. Cytotoxic T-lymphocyte (CTL) and natural killer (NK) assays were also performed. HNSCC tumor growth was significantly inhibited following combined IL-2 gene and cisplatin therapy, when compared with that of the control. The levels of IL-2 protein expressions were increased in combined and single IL-2 treated groups. The activities of cytotoxic T-lymphocytes and natural killers in both the combined treatment group and the IL-2 treated group are higher than those of the controlled group. Combined IL-2 gene and cisplatin therapy can significantly inhibit HNSCC tumor growth in the murine models, and efficiently induces anti-tumor immune reaction of hosts.